Home Business NewsBusiness Top biotech firm set for £2bn London float

Top biotech firm set for £2bn London float

by LLB Editor
31st Mar 21 6:10 am

News that Oxford Nanopore is planning its long-awaited flotation for the second half of 2021 will be sparking a few hopes and dreams for shareholders in IP Group, says AJ Bell Investment Director Russ Mould.

“The intellectual property commercialisation expert holds a 15% stake in Oxford Nanopore, which currently has a £340 million valuation on IP Group’s books, equivalent to a quarter of the company’s entire portfolio of investments, which comprises stakes in over 120 life sciences, technology and renewables companies.

“A successful listing by Oxford Nanopore could conceivably give an uplift to those valuations and thus IP Group’s net asset value (NAV) and share price.

“IP Group’s latest published NAV per share figure is 125.3p, including the company’s £203 million net cash pile, so the shares trade at pretty much book value (a huge contrast to the 50%-plus discount which prevailed when Neil Woodford’s woes compelled his funds to dump 13% of IP Group’s shares so they could raise cash in late 2019).

“The FTSE 250 constituent invests in, and works to commercialise, the intellectual property (IP) developed by British universities.

“A successful float by Oxford Nanopore – the third unicorn with a $1-billion-plus valuation to emerge from IP Group’s investments, after Ceres Power and Hinge Health – would be a huge affirmation of the company’s business model. IP Group exited Ceres Power with a seven-fold profit in 2020, as the firm realised more from sales of investments than it put into them for the second year in a row.”

Leave a Commment

You may also like


Sign up to our daily news alerts

[ms-form id=1]